Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.37 |
| ▸ | TERT | O14746 | 7/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14228347 | 0.90 | HRH3 (0.37) | HRH3TERTKCNH2ALDH1A1MAPT | |
| SCHEMBL9922286 | 0.90 | HRH3 (0.38) | HRH3TERTKCNH2ALDH1A1MAPT | |
| SCHEMBL12161516 | 0.88 | PTGER3 (0.37) | HRH3TERT | |
| SCHEMBL12177102 | 0.88 | HRH3 (0.39) | HRH3KCNH2 | |
| SCHEMBL9922811 | 0.87 | PTGER3 (0.37) | HRH3TERTALDH1A1MAPT | |
| SCHEMBL9922424 | 0.87 | P2RY12 (0.42) | HRH3TERTKCNH2 | |
| SCHEMBL12160785 | 0.87 | PSEN1 (0.42) | HRH3TERTALDH1A1MAPT | |
| SCHEMBL14113768 | 0.85 | HRH3 (0.41) | HRH3TERTKCNH2 | |
| SCHEMBL9922423 | 0.84 | HTT (0.41) | MAPT | |
| SCHEMBL9923241 | 0.84 | HRH3 (0.36) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | HRH3 1858/4885TERT 2585/4885KCNH2 1064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.